Ipilimumab is a monoclonal antibody, more specifically a fully humanized IgG1 antibody produced in mammalian cell culture, to the cytotoxic T lymphocyte antigen-4 (CTLA-4) which activates antitumor immunity by inhibiting this major checkpoint.

The global Ipilimumab market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Ipilimumab volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Ipilimumab market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Ipilimumab Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
PD - L1 Antagonists
CTLA4 Antagonists
Immunocheckpoint Inhibitors
Other

Segment by Application
Cancer
Melanoma

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Gilead
BMS
Ono
Roche
Prestige BioPharma
Avacta
Baxter
Shenyang Sansheng Pharmaceutical